RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 89.5%

Neg 89.5% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and lowers the price target from $19 to $17.